MARKEN ENSURES U.S. CITIZEN IN SOUTH AFRICA HAS ACCESS TO MEDICATION DURING PANDEMIC

Tags:
Travel Restrictions and Supply of Clinical Drug Product Created Critical Situation for Patient  

Unable to return home to the U.S. with limited travel options due to COVID-19, an immunocompromised patient required help obtaining the clinical drug needed for treatment while temporarily living in South Africa. Marken helped clear the complex regulatory hurdles and delivered their required medication to keep the patient enrolled in the trial.

 

GOAL

To deliver clinical study medication from a U.S. investigator site to a patient in a country where the drug is not available, within a short time frame before the patient’s supply ran out.

 

CHALLENGE

The importation of clinical drugs can present complex regulatory hurdles to overcome for Customs clearance into South Africa. The U.S. Embassy and South African Health Products Regulatory Authority (SAPRHA) offices were both closed due to COVID-19. Marken engaged the U.S. Department of State in Washington, D.C. for their assistance to intervene and obtain the required SAPHRA entry approval on the patient’s behalf.

 

SOLUTION

A cross-functional Marken team worked together to outline and coordinate the many regulatory documents and compliance clearance forms needed by SAPRHA. Following several unsuccessful attempts to reach the responsible authorities at SAPRHA, Marken reached out to the U.S. Department of State as well as the U.S. Embassy in South Africa for intervention and assistance.  A designated Marken team member maintained one point of constant communication with the trial sponsor, pharmaceutical company, the U.S. investigator site, and all the internal Marken teams to keep everyone apprised of the process and developments, while maintaining full compliance with all privacy laws. The patient communicated directly with the investigator site for updates.

 

OUTCOME

The patient received their clinical drug supply for the duration of their stay in South Africa, avoiding any disruptions to their trial enrollment and status, or their treatment.

 

About Marken
Marken is a wholly owned subsidiary of the UPS Healthcare division. With Polar Speed and Marken included, the UPS division staffs 128 locations with 5000 employees worldwide. Marken maintains the leading position for Direct to Patient and Home Health care services, biological sample shipments and offers a state-of-the-art GMP-compliant depot network and logistic hubs in 54 locations worldwide for clinical trial product storage and distribution. Marken’s dedicated 1200 staff members manage 85,000 drug product and biological sample shipments every month at all temperature ranges in more than 220 countries. Additional services such as biological kit production, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry.

 

Issued April 2020

Back to Index